LEAWOOD, Kan., July 16, 2019 /PRNewswire/ -- Aratana
Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company
focused on the development and commercialization of innovative
therapeutics for dogs and cats, today announced the voting results
for the three proposals considered and voted upon by its
stockholders at its Special Meeting on July
16, 2019. The Company reported approximately 72%
(35,269,237) of the Company's common stock outstanding as of the
July 14, 2019 record date adopted the
merger agreement.
Approximately 73% (35,769,162) of the Company's outstanding
common stock as of the June 14, 2019
record date was present in person or represented by proxy at the
Special Meeting and of the shares voted, approximately 99% voted in
favor of adopting the merger proposal. A Form 8-K disclosing the
full voting results will be filed with the Securities and Exchange
Commission on July 16, 2019.
The closing of the merger will take place no later than two
business days following when the last of the closing conditions of
the merger have been satisfied or waived. At the close of the
stock-for-stock transaction, Aratana stockholders will receive
0.1481 share of Elanco common stock and one contingent value right
(CVR) for each share of Aratana common stock. The CVR of
$0.25 per Aratana share will be paid
in cash if capromorelin achieves certain sales levels on or before
the end of 2021.
About Aratana Therapeutics
Aratana Therapeutics is a
pet therapeutics company focused on developing and commercializing
innovative therapeutics for dogs and cats. Our mission is to
successfully develop and deliver best-in-class therapeutics,
provide comprehensive service to veterinarians and serve as a
collaborator of choice for human and animal health companies. We
believe our therapeutics are highly differentiated, resolve
recognizable needs in compelling markets and have therapeutic
profiles superior to the standard of care. For more information,
please visit www.aratana.com.
Contacts
For investor inquires:
Rhonda Hellums
rhellums@aratana.com
(913) 353-1026
For media inquiries:
Rachel Reiff
rreiff@aratana.com
(913) 353-1050
Cautionary Statement Regarding Forward-Looking
Statements
Statements in this document that are not
strictly historical, including statements regarding the proposed
acquisition of Aratana, the expected timetable for completing the
transaction, future financial and operating results, benefits and
synergies of the transaction, future opportunities for the combined
businesses and any other statements regarding events or
developments that we believe or anticipate will or may occur in the
future, may be "forward-looking" statements within the meaning of
the Private Securities Litigation Reform Act of 1995, and involve a
number of risks and uncertainties. There are a number of important
factors that could cause actual events to differ materially from
those suggested or indicated by such forward-looking statements and
you should not place undue reliance on any such forward-looking
statements. These factors include risks and uncertainties related
to, among other things: (1) the inability to close the merger in a
timely manner; (2) the inability to complete the merger due to the
failure to obtain Aratana stockholder adoption of the merger
agreement or the failure to satisfy other conditions to completion
of the merger, including required regulatory approvals; (3) the
failure of the transaction to close for any other reason; (4) the
possibility that the integration of Aratana's business and
operations with those of Elanco may be more difficult and/or take
longer than anticipated, may be more costly than anticipated and
may have unanticipated adverse results relating to Aratana's or
Elanco's existing businesses; (5) the effect of the announcement of
the transaction on Elanco's, Aratana's or the combined company's
respective business relationships, operating results and business
generally; (6) diversion of management's attention from ongoing
business concerns; and (7) other factors that may affect future
results of the combined company described in the section entitled
"Risk Factors" in the proxy statement/prospectus to be mailed to
Aratana's stockholders and in Elanco's and Aratana's respective
filings with the U.S. Securities and Exchange Commission ("SEC")
that are available on the SEC's web site located at www.sec.gov,
including the sections entitled "Risk Factors" in Elanco's and
Aratana's Annual Reports on Form 10-K for the fiscal year ended
December 31, 2018. The
forward-looking statements made herein speak only as of the date
hereof and none of Elanco, Aratana or any of their respective
affiliates assumes any obligation to update or revise any
forward-looking statement, whether as a result of new information,
future events and developments or otherwise, except as required by
law.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aratana-therapeutics-stockholders-adopt-merger-agreement-with-elanco-animal-health-300885981.html
SOURCE Aratana Therapeutics, Inc.